Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer – role of radium-223

References

• BrulandØSNilssonSFisherDRLarsenRHHigh-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?Clin Cancer Res20061220 Pt 26250s6257s17062709
   PubMed Web of Science ®Google Scholar
• FinlayIGMasonMDShelleyMRadioisotopes for the palliation of metastatic bone cancer: a systematic reviewLancet Oncol20056639240015925817
   PubMed Web of Science ®Google Scholar
• JamesNDPirrieSBartonDClinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747)J Clin Oncol201331Suppl 18LBA5000
   Google Scholar
• ParkerCNilssonSHeinrichDAlpha emitter radium-223 and survival in metastatic prostate cancerN Engl J Med2013369321322323863050
   PubMed Web of Science ®Google Scholar
• OmlinAPezaroCMukherjiDImproved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomogramsEur Urol20136430030623313031
   PubMed Web of Science ®Google Scholar
• de BonoJSOudardSOzgurogluMPrednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialLancet201037697471147115420888992
   PubMed Web of Science ®Google Scholar
• de BonoJSLogothetisCJMolinaAAbiraterone and increased survival in metastatic prostate cancerN Engl J Med2011364211995200521612468
   PubMed Web of Science ®Google Scholar
• ScherHIFizaziKSaadFIncreased Survival with Enzalutamide in Prostate Cancer after ChemotherapyN Engl J Med2012367131187119722894553
   PubMed Web of Science ®Google Scholar
• KantoffPWHiganoCSShoreNDSipuleucel-T immunotherapy for castration-resistant prostate cancerN Engl J Med2010363541142220818862
   PubMed Web of Science ®Google Scholar
• TannockIFde WitRBerryWRDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerN Engl J Med2004351151502151215470213
   PubMed Web of Science ®Google Scholar
• PetrylakDPTangenCMHussainMHDocetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancerN Engl J Med2004351151513152015470214
   PubMed Web of Science ®Google Scholar
• QuinnDITangenCMHussainMSWOG S0421: Phase III study of docetaxel (D) and atrasentan (A) versus docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer (CRPC)J Clin Oncol302012Suppl; abstr 4511 2012
   Google Scholar
• AraujoJCTrudelGCSaadFOverall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trialJ Clin Oncol2013Suppl 6; abstr LBA8 2013
   PubMedGoogle Scholar
• KellyWKHalabiSCarducciMRandomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401J Clin Oncol201230131534154022454414
   PubMed Web of Science ®Google Scholar
• PetrylakDPFizaziKSternbergCA Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone (DP) With or Without Lenalidomide (LEN) in Patients with Castrate-Resistant Prostate Cancer (CRPC): The MAINSAIL TrialesMO Conference 2012 LBA242012
   Google Scholar
• TannockIFizaziKIvanovSAflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): Results from the multinational phase III trial (VENICE)J Clin Oncol312013Suppl 6; abstr 13 2013
   Web of Science ®Google Scholar
• Bahl AMSMalikSBirtleACabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): Interim safety and quality-of-life (QOL) data from the UK early access program (NCT01254279)J Clin Oncol201230Suppl 5; abstr 44
   Web of Science ®Google Scholar
• AttardGCooperCSde BonoJSSteroid hormone receptors in prostate cancer: a hard habit to break?Cancer Cell200916645846219962664
   PubMedGoogle Scholar
• NelsonPSMolecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancerJ Clin Oncol201230664464622184375
   PubMed Web of Science ®Google Scholar
• MontgomeryRBMostaghelEAVessellaRMaintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growthCancer Res200868114447445418519708
   PubMed Web of Science ®Google Scholar
• TitusMASchellMJLihFBTomerKBMohlerJLTestosterone and dihydrotestosterone tissue levels in recurrent prostate cancerClin Cancer Res200511134653465716000557
   PubMed Web of Science ®Google Scholar
• LockeJAGunsESLubikAAAndrogen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancerCancer Res200868156407641518676866
   PubMed Web of Science ®Google Scholar
• DarshanMSLoftusMSThadani-MuleroMTaxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancerCancer Res201171186019602921799031
   PubMed Web of Science ®Google Scholar
• O’DonnellAJudsonIDowsettMHormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancerBr J Cancer200490122317232515150570
   PubMed Web of Science ®Google Scholar
• RyanCJSmithMRde BonoJSAbiraterone in Metastatic Prostate Cancer without Previous ChemotherapyN Engl J Med201336813814823228172
   PubMed Web of Science ®Google Scholar
• TranCOukSCleggNJDevelopment of a second-generation antiandrogen for treatment of advanced prostate cancerScience2009324592878779019359544
   PubMed Web of Science ®Google Scholar
• BeerTMAASternbergCNHiganoCSEnzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of phase III PREVAIL studyJ Clin Oncol201432Suppl 4 LBA1
   PubMedGoogle Scholar
• SmallEJFratesiPReeseDMImmunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cellsJ Clin Oncol200018233894390311099318
   PubMed Web of Science ®Google Scholar
• FizaziKCarducciMSmithMDenosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyLancet2011377976881382221353695
   PubMed Web of Science ®Google Scholar
• SmithMRSaadFColemanRDenosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trialLancet20123799810394622093187
   PubMed Web of Science ®Google Scholar
• NilssonSLarsenRHFossaSDFirst clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastasesClin Cancer Res200511124451445915958630
   PubMed Web of Science ®Google Scholar
• McDevittMRSgourosGFinnRDRadioimmunotherapy with alpha-emitting nuclidesEur J Nucl Med1998259134113519724387
   PubMedGoogle Scholar
• SartorOReidRHBushnellDLQuickDPEllPJSafety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone painCancer2007109363764317167764
   PubMed Web of Science ®Google Scholar
• HenriksenGFisherDRRoeskeJCBrulandØSLarsenRHTargeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in miceJ Nucl Med200344225225912571218
   PubMed Web of Science ®Google Scholar
• HenriksenGBreistølKBrulandØSFodstadØLarsenRHSignificant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases modelCancer Res200262113120312512036923
   PubMed Web of Science ®Google Scholar
• HindorfCChittendenSAksnesAKParkerCFluxGDQuantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastasesNucl Med Commun201233772673222513884
   PubMed Web of Science ®Google Scholar
• HafeezSParkerCRadium-223 for the treatment of prostate cancerExpert Opin Investig Drugs2013223379387
   PubMed Web of Science ®Google Scholar
• DauerLTWilliamsonMJHummJRadiation Safety Considerations for the Use of 223RaCl2 DE in Men with Castration-resistant Prostate CancerHealth Phys2014106449450424562070
   PubMed Web of Science ®Google Scholar
• HarrisonMRWongTZArmstrongAJGeorgeDJRadium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone diseaseCancer Manag Res2013511423326203
   PubMedGoogle Scholar
• NilssonSFranzenLParkerCBone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II studyLancet Oncol20078758759417544845
   PubMed Web of Science ®Google Scholar
• NilssonSFranzenLParkerCTwo-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastasesClin Genitourin Cancer2013111202623021204
   PubMed Web of Science ®Google Scholar
• ParkerCNSHeinrichDO’SullivanJMUpdated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA)J Clin Oncol201230SupplLBA4512
   Web of Science ®Google Scholar
• NilssonSVNSartorAOBottomleyD1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 ALSYMPCA studyJ Clin Oncol201432Suppl 4; abstr 9
   Google Scholar
• NilssonSSABrulandOSFangFAksnesAKCiscoPParkerCPain analyses from the phase III ransomized ALSYMPCA study with radium-223 dichloride (radium-223) in castration-resistant prostate cancer (CRPC) patients with bone metastasisJ Clin Oncol201331Suppl 15
   Google Scholar
• WissingMDvan LeeuwenFWvan der PluijmGGelderblomHRadium-223 chloride: Extending life in prostate cancer patients by treating bone metastasesClin Cancer Res201319215822582724052017
   PubMedGoogle Scholar
• MohlerJLKantoffPWArmstrongAJProstate cancer, version 1.2014J Natl Compr Canc Netw201311121471147924335682
   PubMed Web of Science ®Google Scholar